Psychedelic medicines: are they gaining traction in Europe?
European Pharmaceutical Review
APRIL 13, 2023
The Schedule 1 classification means that these substances cannot be administered by doctors and, though they may be used for the purposes of research a government licence is often required. The US Food and Drug Administration (FDA) has decided to fast-track psilocybin for depression, with full support from President Biden’s administration.
114 
Let's personalize your content